- Home
- HRMY vs ADUS Comparison
HRMY vs ADUS Comparison
Compare HRMY & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ADUS
- Stock Information
- Founded
- HRMY 2017
- ADUS 1979
- Country
- HRMY United States
- ADUS United States
- Employees
- HRMY N/A
- ADUS N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ADUS Medical/Nursing Services
- Sector
- HRMY Health Care
- ADUS Health Care
- Exchange
- HRMY Nasdaq
- ADUS Nasdaq
- Market Cap
- HRMY 1.6B
- ADUS 1.8B
- IPO Year
- HRMY 2020
- ADUS 2009
- Fundamental
- Price
- HRMY $34.09
- ADUS $110.70
- Analyst Decision
- HRMY Strong Buy
- ADUS Buy
- Analyst Count
- HRMY 8
- ADUS 10
- Target Price
- HRMY $52.88
- ADUS $143.50
- AVG Volume (30 Days)
- HRMY 729.2K
- ADUS 186.8K
- Earning Date
- HRMY 05-06-2025
- ADUS 05-05-2025
- Dividend Yield
- HRMY N/A
- ADUS N/A
- EPS Growth
- HRMY 13.13
- ADUS 9.84
- EPS
- HRMY 2.62
- ADUS 4.42
- Revenue
- HRMY $744,852,000.00
- ADUS $1,211,561,000.00
- Revenue This Year
- HRMY $20.06
- ADUS $24.03
- Revenue Next Year
- HRMY $18.40
- ADUS $5.80
- P/E Ratio
- HRMY $12.76
- ADUS $25.43
- Revenue Growth
- HRMY 20.62
- ADUS 11.38
- 52 Week Low
- HRMY $26.47
- ADUS $88.96
- 52 Week High
- HRMY $41.61
- ADUS $136.72
- Technical
- Relative Strength Index (RSI)
- HRMY 69.87
- ADUS 67.83
- Support Level
- HRMY $29.82
- ADUS $103.15
- Resistance Level
- HRMY $30.61
- ADUS $101.25
- Average True Range (ATR)
- HRMY 1.15
- ADUS 3.20
- MACD
- HRMY 0.71
- ADUS 1.14
- Stochastic Oscillator
- HRMY 98.91
- ADUS 88.31
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.